Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ralph HB Benedict, Pamela Vo, Nicholas Adlard, Olwyn Grennan, Ashley Enstone, Daisy Bridge, Robin Wyn & Stanley L Cohan. (2024) Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study. ClinicoEconomics and Outcomes Research 16, pages 55-67.
Read now
Read now
S. Montgomery, F. Woodhouse, U. Vudumula, K. Gudala, M. Duddy & M. Kroes. (2022) Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK. Journal of Medical Economics 25:1, pages 669-678.
Read now
Read now
Jeremy Chataway, Niamh Murphy, Vivek Khurana, Helen Schofield, John Findlay & Nicholas Adlard. (2021) Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities. Current Medical Research and Opinion 37:6, pages 995-1004.
Read now
Read now
Articles from other publishers (5)
Tatchaporn Ongphichetmetha, Saharat Aungsumart, Sasitorn Siritho, Metha Apiwattanakul, Jantima Tanboon, Natthapon Rattanathamsakul, Naraporn Prayoonwiwat & Jiraporn Jitprapaikulsan. (2024) Tumefactive demyelinating lesions: a retrospective cohort study in Thailand. Scientific Reports 14:1.
Crossref
Crossref
Sarah A. Morrow, Paola Kruger, Dawn Langdon & Nektaria Alexandri. (2023) What Is the True Impact of Cognitive Impairment for People Living with Multiple Sclerosis? A Commentary of Symposium Discussions at the 2020 European Charcot Foundation. Neurology and Therapy 12:5, pages 1419-1429.
Crossref
Crossref
Karolina Kania, Wojciech Ambrosius, Wojciech Kozubski & Alicja Kalinowska-Łyszczarz. (2023) The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review. Frontiers in Neurology 14.
Crossref
Crossref
Antonio Filipe Macedo, Amanda Hellström, Robert Massof, Hanna Tuvesson, Mikael Rask, Pedro Lima Ramos, Jalal Safipour, Ina Marteinsdottir, Evalill Nilsson, Cecilia Fagerström & Kristofer Årestedt. (2022) Predictors of problems reported on the EQ-5D-3L dimensions among people with impaired vision in northern Portugal. Health and Quality of Life Outcomes 20:1.
Crossref
Crossref
Juan Raúl García Bónitto, Oscar Daniel Ayala & Laura Catalina Botero. (2022) Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia. Multiple Sclerosis and Related Disorders 61, pages 103780.
Crossref
Crossref